Abstract:Copper is an essential trace metal for biological processes in humans and animals. A low level of copper detection at physiological pH using fluorescent probes is very important for in vitro applications, such as the detection of copper in water or urine, and in vivo applications, such as tracking the dynamic copper concentrations inside cells. Copper homeostasis is disrupted in neurological diseases like Alzheimer's disease, and copper forms aggregates with amyloid beta (Ab42) peptide, resulting in senile plaques in Alzheimer's brains. Therefore, a selective copper detector probe that can detect amyloid beta peptide-copper aggregates and decrease the aggregate size has potential uses in medicine. We have developed a series of Cu2+-selective low fluorescent to high fluorescent tri and tetradentate dentate ligands and conjugated them with a peptide ligand to amyloid-beta binding peptide to increase the solubility of the compounds and make the resultant compounds bind to Cu2+–amyloid aggregates. The copper selective compounds were developed using chemical scaffolds known to have high affinity and selectivity for Cu2+, and their conjugates with peptides were tested for affinity and selectivity towards Cu2+. The test results were used to inform further improvement of the next compound. The final Cu2+ chelator–peptide conjugate we developed showed high selectivity for Cu2+ and high fluorescence properties. The compound bound 1:1 to Cu2+ ion, as determined from its Job's plot. Fluorescence of the ligand could be detected at nanomolar concentrations. The effect of this ligand on controlling Cu2+–Ab42 aggregation was studied using fluorescence assays and microscopy. It was found that the Cu2+–chelator–peptide conjugate efficiently reduced aggregate size and, therefore, acted as an inhibitor of Ab42-Cu2+ aggregation. Since high micromolar concentrations of Cu2+ are present in senile plaques, and Cu2+ accelerates the formation of toxic soluble aggregates of Ab42, which are precursors of insoluble plaques, the developed hybrid molecule can potentially serve as a therapeutic for Alzheimer's disease.

Enantiomers of Cysteine-Modified SeNPs (d/lsenps) As Inhibitors of Metal-Induced Aβ Aggregation in Alzheimer's Disease.

Chiral Penicillamine-Modified Selenium Nanoparticles Enantioselectively Inhibit Metal-Induced Amyloid Β Aggregation for Treating Alzheimer’s Disease

Se/Ru nanoparticles as inhibitors of metal-induced Aβ aggregation in Alzheimer's disease

Chiral Metallohelical Complexes Enantioselectively Target Amyloid Β for Treating Alzheimer’s Disease

Enantioselective Modulation of Amyloid Burden and Memory Deficits by Chiral Polyoxometalates for Alzheimer's Disease Treatment

Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer's disease

Chiral carbon dots based on ternary carbon sources: A multifunctional therapeutic agent for Cu2+-induced Alzheimer's disease

C3N Nanodots Inhibits Aβ Peptides Aggregation Pathogenic Path in Alzheimer's Disease.

Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease

A Novel Synthesis of Selenium Nanoparticles Encapsulated PLGA Nanospheres with Curcumin Molecules for the Inhibition of Amyloid Β Aggregation in Alzheimer's Disease

Metallosupramolecular complex targeting an α/β discordant stretch of amyloid β peptide

Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer’s Disease

Chiral Metallo‐Supramolecular Complex Directed Enantioselective Self‐Assembly of β‐Sheet Breaker Peptide for Amyloid Inhibition

Chiral effect on Aβ fibrillation from molecular-scale to nanoscale

Metallosupramolecular Complex Targeting an Alpha/Beta Discordant Stretch of Amyloid Beta Peptide

A Chiral Nanocomplex for Multitarget Therapy to Alleviate Neuropathology and Rescue Alzheimer's Cognitive Deficits

Synthesis and Evaluation of Selegiline Derivatives As Monoamine Oxidase Inhibitor, Antioxidant and Metal Chelator Against Alzheimer's Disease.

A Copper-Selective Sensor and Its Inhibition of Copper-Amyloid Beta Aggregation

Rational Design of Dual-Functionalized Gd@C82 Nanoparticles to Relieve Neuronal Cytotoxicity in Alzheimer's Disease Via Inhibition of Aβ Aggregation.

A multifunctional anti-AD approach: Design, synthesis, X-ray crystal structure, biological evaluation and molecular docking of chrysin derivatives

Liberation of copper from amyloid plaques: Making a risk factor useful for alzheimers disease treatment